Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery) (DHAPS)

  • STATUS
    Recruiting
  • days left to enroll
    83
  • participants needed
    200
  • sponsor
    Washington University School of Medicine
Updated on 20 April 2022
nausea
gonadotropin
fluid restriction
cyst
growth hormone
adenoma
hormone secreting
vomiting
headache
prolactin
ACTH
coma
pituitary adenoma
pituitary tumor
pituitary disorders

Summary

Hyponatremia is defined as sodium below the normal range of 135-145. Symptomatically, it can cause patients to experience a wide range of symptoms including lethargy, headache, nausea, vomiting and in severe cases coma and even death. The goal of this study is to prospectively compare two approaches to the postoperative fluid management of patients undergoing transsphenoidal resection of a pituitary tumor or cyst to decrease the occurrence of postoperative delayed hyponatremia. One group will be placed on moderate fluid restriction and the other group will be placed on ad lib fluid intake.

Description

Any adult patient with a pituitary adenoma (either non-functioning, prolactin-secreting, growth hormone secreting, gonadotropin secreting, or TSH (thyroid stimulating hormone) secreting) or cyst scheduled to undergo transsphenoidal resection will be included in the study. Patients with chronic hyponatremia will be excluded.

Patients will be randomly assigned to one of two groups:

Group 1: these patients will be treated with moderate fluid restriction (1000 ml/24 hours for patients <100kg and 1200 ml of fluid/24 hours for >100 kg starting on postoperative day 1. Fluid restriction will be aborted if diabetes insipidus occurs. Diabetes insipidus occurs if a patient does not produce enough ADH (anti-diuretic hormone) which is needed to concentrate the urine. Diabetes insipidus causes increased urination and increased thirst and can cause hypernatremia (an increased sodium level). A person will be diagnosed with diabetes insipidus if they meet all of the following criteria: serum sodium level > 146, dilute urine with a urine specific gravity < 1.003 and increased urine output defined by urine output > 300cc/hour for 2 consecutive hours( or > 6 liter/24 hours).

Group 2: these patients will not be placed on fluid restriction, they will be allowed to drink water freely after surgery.

All patients will be started on D5 ½ normal saline IV fluids (Weight based) and will be allowed to eat and drink starting on POD 1.

All the patients will receive a thirst questionnaire that will be completed daily starting on POD 1 until POD 13. The intensity of thirst will be assessed on a scale of 1--10, with 1 being no thirst, 5 being normal thirst and 10 being unbearable thirst.

Patients will have basic metabolic panels checked on post-surgical days 1, 3, 7, 10 and 13.

Details
Condition Hyponatremia, Hyponatremic, Pituitary Tumor, Pituitary, Surgery
Treatment Fluid Restricted Group
Clinical Study IdentifierNCT03636568
SponsorWashington University School of Medicine
Last Modified on20 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

• Any adult patient with a pituitary adenoma or cyst (either non-functioning
prolactin-secreting, growth hormone secreting, ACTH (adrenocorticotropic
hormone)-secreting, gonadotropin secreting, or TSH secreting) scheduled to undergo
pituitary resection

Exclusion Criteria

Patients with a history of chronic hyponatremia
Patients with a history of SIADH (syndrome of inappropriate antidiuretic hormone)
Patients with diabetes insipidus or patients receiving DDAVP
except if secondary to hypothyroidism or adrenal insufficiency, or in association with
prior TSS
Patients without an intact thirst mechanism
Patients with CKD (chronic kidney disease) stage III, IV or V
Patients with untreated adrenal insufficiency or hypothyroidism
Patients with class III or IV heart failure
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note